Data collection

At study enrollment, each participant of ≥16 years received instructions to install the COVapp on a mobile device. The COVapp is a custom made application compatible with Apple and Android systems, developed by the UMCU. A unique username and password providing access to the application were sent by email. Via this application, participants could fill in several questionnaires and daily symptom diaries (self-reported; fever, coughing, sore throat, cold, dyspnea, headache, muscle pain, cold shivers, fatigue, anosmia (since July 7, 2020) and diarrhea). Parents or caregivers completed the questionnaires and symptom diaries for their children aged <16 years, or for family members without access to the app. At start of the study, per household a questionnaire was filled out containing questions regarding household characteristics and living situation. A nose-throat swab (NTS), a capillary blood sample on filter paper (dried blood spot) and a baseline questionnaire capturing demographics, comorbidities and views on prevention measures were collected from each household member irrespective of symptoms. For children aged 0-2 year, also a stool sample was collected seven days after enrollment. A daily follow-up of disease symptoms started for at least 21 days. Symptom followup was prolonged in case of new acute respiratory illness (ARI) episode in the household emerged. At the beginning of a new ARI episode the app generated a request for a nose-throat swab from the person with ARI disease (and an additional stool sample for children 0-2 years seven days after symptom onset) and scoring lists. At the end of the ARI episode a questionnaire about disease progression and self-reported transmission prevention behaviors popped up. Follow-up ended after 21 days or 21 days after the last date of onset of symptoms in the household. Ten days later a capillary blood sample was collected for each household member again. The mobile application automatically generated requests for swabs, blood or stools during the study. The materials for self-sampling were delivered at the beginning of the study at the home address, stored in home freezers (-15 °C) during follow-up and picked-up at the end of the study by the study team. All data entered to the app were stored in an online secured web system.

Laboratory analysis

At arrival on the lab blood samples and swabs were stored at -80 °C instantly until further analysis. Swabs were tested separately for the presence of SARS-CoV-2 by real-time PCR as described in detail elsewhere.[1] Briefly, 100 µl of a clinical specimen was mixed with proteinase K and 10 µl of a known amount of phocine herpesvirus (DNA) and Phocine distemper virus (RNA)—to monitor the efficient extraction of nucleic acids (NA) — and incubated for 15 min at 56°C. Subsequently, NA extraction was performed by using the specific A protocol on the NucliSens EasyMag (BioMérieux, Marcy-l'Etoile, France). The nucleic acid was then eluted in 70 µl of elution buffer and directly used for cDNA synthesis and real-time TagMan PCR. Stool samples were mechanically pretreated by beating them through a membrane prior to the proteinase K pretreatment to optimize nucleic acid extraction. A 20-µl reaction contained 5 µl of NA extract and 5 µl of the TaqMan Fast Virus 1-Step Master Mix 4x (Thermo Fisher, Brussels, Belgium). Primer and probe sequences, as well as optimized concentrations were used as described by Corman et al.[1] All oligonucleotides were synthesized and provided by Tib Molbiol, Berlin, Germany. Thermal cycling was performed at 55°C for 10 min for reverse transcription, followed by 95°C for 3 min and then 45 cycles of 95°C for 15s, 58°C for 30s on a LightCycler 480 instrument (Roche) for the detection of the SARS-CoV-2 E-gene. In addition, NA extracts were analysed for the presence of RNAseP to check the quality of the specimens. Cycle threshold values (Ct-values) >35 were designated as invalid. The 20-µl reaction contained also 5 µl of NA extract and 5 µl of the TaqMan Fast Virus 1-Step Master Mix 4x (Thermo Fisher). Primer and probe sequences, as well as optimized concentrations were used as described by the CDC.[2] Thermal cycling was performed at 50°c for 15 min for reverse transcription, followed by 2 min at 95°C and then 45 cycles of 95°C for 15 sec and 30 sec at 55°C on the LightCycler 480 instrument (Roche). Ctvalues for SARS-CoV-2 ≤40 is used as cut-off to interpreted positively.

Dried blood spot specimens were tested by multiplex protein microarray for antibodies targeting recombinant SARS-CoV-2 spike (S) ectodomain and S1 subunit antigens expressed JDM Verberk & MLA de Hoog et al. (2021) Transmission of SARS-CoV-2 within households: a prospective cohort study in the Netherlands and Belgium–Interim results

in HEK293 cells as described earlier.[3-5] Briefly, antigens were printed on nitrocellulose coated slides and incubated for 1 hour at 37 °C with Blotto Blocker (Pierce, United States of America). Slides were washed with phosphate buffered saline (PBS) containing 0.1% Tween-20 between each step. DBS were eluted in PBS with 5% Tween-20 for one hour, diluted in Blotto Blocker with 0.1% Tween-20, and tested on the printed slides in a final 1:40 dilution for 1 hour at 37 degrees Celsius. This was followed by an incubation step with goat anti-human lgG (Fab specific) conjugated with AF647 (Jackson ImmunoResearch, United Kingdom). Slides were scanned using a Powerscanner (Tecan, Switzerland) and analyzed using ScanArray Express software (PerkinElmer, Waltham, USA). The use of DBS was compared to serum on the protein microarray platform by testing DBS specimens 1:40 and serial diluted serum specimens obtained from 8 individuals against a panel of endemic and epidemic human coronavirus recombinant antigens. The relative fluorescence units (RFU) of DBS specimens showed a good correlation and a similar level compared to 1:80 serum for various antigens. Specimens with a S1 antigen signal exceeding 13,000 relative RFU and a S ectodomain signal exceeding 2,000 RFU were considered positive.

REFERENCES

- 1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25(3):2000045.
- 2. Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus: Centers for Disease Control and Prevention. https://www.who.int/docs/default-source/coronaviruse/uscdcrt-pcr-panel-for-detection-instructions.pdf. Accessed 26 March 2021.
- 3. de Bruin E, Loeber JG, Meijer A, Castillo GM, Cepeda ML, Torres-Sepúlveda MR, et al. Evolution of an influenza pandemic in 13 countries from 5 continents monitored by protein microarray from neonatal screening bloodspots. *J Clin Virol*. 2014;61(1):74-80.
- 4. Westerhuis BM, de Bruin E, Chandler FD, Ramakers CRB, Okba NMA, Li W, et al. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands. *medRxiv*. 2020:2020.08.21.20177857.
- 5. Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke GJ, Meyer B, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. *Lancet Infect Dis.* 2013;13(10):859-66.